Finkelstein Thompson LLP Investigates Potentially Unfair Buyout of ArthroCare Corporation

WASHINGTON--(BUSINESS WIRE)--The law firm of Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of ArthroCare Corporation (Nasdaq: ARTC) (“ArthroCare” or “the Company”), concerning the Company’s proposed acquisition by Smith & Nephew plc. Under the terms of the proposal, ArthroCare shareholders will receive $48.25 in cash for each share of ArthroCare they own. At least one analyst has set a target price of $60.00 for ArthroCare shares. The entire transaction is valued at approximately $1.7 billion.